ESALF - Eisai files application in Japan for Alzheimer's drug lecanemab
- Eisai ( OTCPK:ESALY )( OTCPK:ESALF ) has submitted a marketing authorization application to regulators in Japan for the Alzheimer's disease treatment lecanemab.
- The application is supported by results from the phase III Clarity AD study and a phase IIb study, both of which showed lecanemab led to a reduction in clinical decline in early Alzheimer's .
- The Japanese drugmaker just filed a lecanemab application with the European Medicines Agency on Jan. 11 .
- With US partner Biogen ( BIIB ), the treatment, known as Leqembi, was approved by the US FDA earlier in January .
For further details see:
Eisai files application in Japan for Alzheimer's drug lecanemab